MediPrint Ophthalmics moves forward with LL-BMT1, sustained drug delivery contact lenses for glaucoma

(Image credit: Adobe Stock / ©terovesalainen)

MediPrint Ophthalmics is advancing its innovative glaucoma program following the successful completion of its Phase 2b clinical trial for LL-BMT1. The company anticipates meeting with the US Food and Drug Administration (FDA) in 2025 to discuss preparations for Phase 3 clinical studies.

LL-BMT1 is a sustained drug delivery approach via a 3D-printed, drug-eluting contact lens to be used in glaucoma care. The company notes in its press release that this candidate could significantly reduce treatment burden and enhance patient compliance. The Phase 2b trial demonstrated that LL-BMT1 provided similar therapeutic results as a once-a-week solution to the comparator, 0.01% bimatoprost eye drop, offering a significant dosing advantage over one or multiple-times-per-day eye drop regimens.¹

Patent awarded to MediPrint

MediPrint was issued US Patent No. 12,178,904 by the US Patent and Trademark Office on December 31, 2024. This patent covers MediPrint’s proprietary chemistry related to the sustained delivery of prostaglandins from contact lenses and extends the company’s patent protection through 2043. With this issuance, MediPrint’s global patent portfolio encompasses 29 granted patents with additional patents pending.¹

Presentation at Glaucoma 360 New Horizons Forum

MediPrint participated in the Glaucoma 360 New Horizons Forum in San Francisco, California on February 7, 2025. The company presented developments in sustained drug delivery technology and discussed how LL-BMT1 could advance the standard of care for patients with glaucoma.¹

Reference:

1. MediPrint Ophthalmics Advances Glaucoma Program, Expands Patent Portfolio, and Prepares for Key Industry Presentation. February 7, 2025. Accessed February 12, 2025. https://www.biospace.com/press-releases/mediprint-ophthalmics-advances-glaucoma-program-expands-patent-portfolio-and-prepares-for-key-industry-presentation